RY 161.29 0.8315% SHOP 116.7 1.6108% TD 83.65 0.553% ENB 61.82 1.2613% BN 68.755 0.8729% TRI 248.88 1.754% CNQ 38.22 0.6054% CP 103.1 0.4775% CNR 138.9 -0.0576% BMO 129.44 1.1013% BNS 65.52 0.7845% CSU 4654.3901 1.9582% CM 81.81 1.3755% MFC 40.37 1.0766% ATD 69.68 -0.9805% NGT 76.14 0.2106% TRP 67.93 2.0123% SU 46.68 0.4735% WCN 273.82 0.8397% L 206.99 -1.499%
Last update at 2025-04-15T16:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Curaleaf Launches Anthem, a Classic Pre-Roll Brand Celebrating American Grown Cannabis
Mon 14 Apr 25, 11:45 AMCuraleaf to Report First Quarter 2025 Financial and Operational Results
Mon 07 Apr 25, 08:30 PMSelect FormulaX: Curaleaf's New Hemp THC Energy Drink Hits the Market
Mon 31 Mar 25, 11:45 AMCuraleaf Reports Fourth Quarter and Full Year 2024 Results
Mon 03 Mar 25, 09:00 PMThe Hemp Company by Curaleaf Expands Beverage Sales to Over 100 Total Wine Stores
Thu 27 Feb 25, 12:50 PMCuraleaf Celebrates New Sedona Dispensary
Thu 27 Feb 25, 12:45 PMCatch The High Tide: Curaleaf Launches 'Reef' Flower Brand in Florida
Mon 03 Feb 25, 12:45 PMCuraleaf to Report Fourth Quarter and Full Year 2024 Financial and Operational Results
Tue 28 Jan 25, 12:45 PMBreakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Income before tax | -167.85517M | -112.59470M | -77.97841M | 41.31M | -60.75731M |
Minority interest | - | - | - | - | - |
Net income | -379.52792M | -481.81467M | -258.19370M | -76.67011M | -89.22589M |
Selling general administrative | 392.79M | 408.15M | 373.90M | 234.88M | - |
Selling and marketing expenses | 41.99M | 39.75M | 41.84M | 23.27M | - |
Gross profit | 644.70M | 667.70M | 607.67M | 142.15M | 16.15M |
Reconciled depreciation | - | - | - | - | - |
Ebit | 57.88M | 84.60M | 73.43M | -204.10982M | -166.46592M |
Ebitda | 343.90M | 300.25M | 240.89M | -97.19068M | -117.09737M |
Depreciation and amortization | 286.02M | 215.64M | 167.45M | 106.92M | 49.37M |
Non operating income net other | - | - | - | - | - |
Operating income | 57.88M | 84.60M | 73.43M | -204.10982M | -166.46592M |
Other operating expenses | 1759.65M | 1575.81M | 1426.01M | 1044.62M | 459.73M |
Interest expense | 100.38M | 88.84M | 90.26M | 69.00M | 32.84M |
Tax provision | - | - | - | - | - |
Interest income | - | - | - | - | - |
Net interest income | - | - | - | - | - |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 154.66M | 232.80M | 191.13M | 117.43M | 31.92M |
Total revenue | 1817.53M | 1660.41M | 1499.45M | 840.51M | 293.27M |
Total operating expenses | 586.82M | 583.10M | 534.24M | 346.26M | 182.62M |
Cost of revenue | 1172.83M | 992.71M | 891.78M | 698.36M | 277.11M |
Total other income expense net | -225.73380M | -197.19955M | -151.41329M | 245.42M | 105.71M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | - | - | - | - | - |
Net income applicable to common shares | - | - | - | - | - |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 4083.15M | 4626.56M | 3922.17M | 3013.65M | 955.61M |
Intangible assets | 1172.44M | 1213.30M | 1010.01M | 707.63M | - |
Earning assets | - | - | - | - | - |
Other current assets | 63.55M | 283.57M | 147.04M | 87.45M | 8.40M |
Total liab | 2538.68M | 2728.52M | 1818.91M | 1255.77M | 432.44M |
Total stockholder equity | 1385.38M | 1733.94M | 1952.98M | 1756.46M | 530.06M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 452.51M | 451.79M | 160.26M | 90.74M | 64.27M |
Common stock | - | - | 2811.70M | 2235.12M | 899.55M |
Capital stock | - | - | - | - | - |
Retained earnings | -1504.19427M | -1164.65269M | -618.25887M | -242.15045M | -172.35104M |
Other liab | - | - | - | - | - |
Good will | 826.27M | 847.02M | 765.26M | 686.46M | 89.90M |
Other assets | 0.00000M | 0.00000M | - | - | - |
Cash | 121.07M | 221.10M | 378.10M | 93.69M | 54.87M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 651.43M | 673.23M | 399.46M | 280.44M | 137.79M |
Current deferred revenue | 1.14M | 0.92M | 175.80M | 101.47M | 19.60M |
Net debt | 1327.04M | 1333.85M | 645.22M | 642.30M | 202.03M |
Short term debt | 93.19M | 111.06M | 29.62M | 28.30M | 37.39M |
Short long term debt | - | - | - | - | - |
Short long term debt total | 1448.11M | 1554.95M | 1023.32M | 736.00M | 256.90M |
Other stockholder equity | 2905.23M | 2923.78M | 76.55M | -6.63499M | -6.75347M |
Property plant equipment | - | - | - | - | - |
Total current assets | 551.97M | 884.00M | 917.83M | 532.36M | 193.90M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | - | - | - | - |
Short term investments | - | - | - | - | - |
Net receivables | 82.65M | 61.22M | 79.25M | 40.10M | 23.78M |
Long term debt | - | - | - | - | - |
Inventory | 284.70M | 318.12M | 313.45M | 311.11M | 106.86M |
Accounts payable | 104.59M | 109.47M | 33.79M | 59.93M | 16.52M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -15.65837M | -25.19394M | -317.00644M | -229.87801M | -190.38754M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | - |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 589.76M | 673.50M | 489.09M | 554.76M | 252.17M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 3531.18M | 3742.55M | 3004.34M | 2481.30M | 761.70M |
Capital lease obligations | - | - | - | - | - |
Long term debt total | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Investments | - | - | - | - | - |
Change to liabilities | - | - | - | - | - |
Total cashflows from investing activities | - | - | - | - | - |
Net borrowings | - | - | - | - | - |
Total cash from financing activities | -96.07477M | 54.41M | 457.79M | 300.55M | 23.96M |
Change to operating activities | - | - | - | - | - |
Net income | -310.17831M | -336.49918M | -258.19370M | -76.67011M | -89.22589M |
Change in cash | -100.02546M | -157.00075M | 284.40M | 38.83M | -309.27864M |
Begin period cash flow | 221.10M | 378.10M | 93.69M | 54.87M | 364.14M |
End period cash flow | 121.07M | 221.10M | 378.10M | 93.69M | 54.87M |
Total cash from operating activities | 101.58M | 60.41M | -73.06754M | 16.57M | -50.84804M |
Issuance of capital stock | - | - | - | - | - |
Depreciation | 286.02M | 215.64M | 167.45M | 106.92M | 49.37M |
Other cashflows from investing activities | - | - | - | - | - |
Dividends paid | - | - | - | - | - |
Change to inventory | 13.30M | -20.96375M | -116.75134M | -123.91477M | -38.14299M |
Change to account receivables | 0.15M | -26.32348M | -31.66552M | 7.99M | -9.21265M |
Sale purchase of stock | - | - | - | -2.50800M | -1.17165M |
Other cashflows from financing activities | -42.30594M | -19.65538M | -6.25236M | 53.60M | 32.97M |
Change to netincome | - | - | - | - | - |
Capital expenditures | 94.89M | 175.29M | 215.59M | 169.37M | 108.91M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | 46.08M | 85.98M | -69.94950M | 38.35M | -18.56595M |
Stock based compensation | 20.01M | 28.02M | 39.48M | 29.36M | - |
Other non cash items | 675.60M | 528.33M | 597.15M | 248.67M | 143.73M |
Free cash flow | 6.69M | -114.87555M | -288.65313M | -152.79835M | -159.75315M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
CURA Curaleaf Holdings Inc. |
0.06 5.41% | 1.17 | - | 138.89 | 1.62 | 1.66 | 1.73 | 10.18 |
BHC Bausch Health Companies Inc |
-0.01 0.17% | 6.00 | - | 2.23 | 0.50 | 18.74 | 2.56 | 9.13 |
TLRY Tilray Inc |
-0.01 1.49% | 0.66 | - | 1000.00 | 2.17 | 0.36 | 1.69 | -2.299 |
CRON Cronos Group Inc |
0.03 1.05% | 2.40 | - | - | 10.18 | 0.70 | 0.02 | -1.9458 |
WEED Canopy Growth Corp |
-0.01 0.70% | 1.42 | - | - | 2.77 | 1.22 | 3.58 | -1.5049 |
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
420 Lexington Avenue, New York, NY, United States, 10170
Name | Title | Year Born |
---|---|---|
Mr. Boris Alexis Jordan | CEO & Chairman | 1966 |
Mr. Joseph F. Lusardi | Executive Vice-Chairman | 1975 |
Mr. Edward Kremer | Chief Financial Officer | 1972 |
Mr. Peter Laurence Clateman J.D. | Chief Legal Officer | 1968 |
Mr. Matthew S. Darin | Special Advisor | NA |
Mr. Camilo Russi Lyon | Chief Investment Officer | NA |
Ms. Christine Taylor | Chief Accounting Officer | NA |
Mr. Jakob Feinstein | Manager of Investor Relations | NA |
Mr. James S. Shorris | Chief Compliance Officer | 1961 |
Ms. Kate Lynch | Executive Vice President of Marketing | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.